Skip to main content

Table 5 Clinical characteristics according to treatment with antimalarials at the study point

From: Predictors of major infections in systemic lupus erythematosus

  Antimalarials P value
  Yes (n = 146) No (n = 103)  
Age at diagnosis (years) 34 (14) 40 (18) <0.01
Female sex 131/146 (89) 63/103 (86) 1.00
Nephritis ever 35/146 (24) 50/103 (48) <0.01
Lung involvement ever 11/146 (7.5) 13/103 (12.6) 0.26
Thrombocytopenia ever 24/146 (16) 17/103 (26) 0.08
Leukopenia ever 94/146 (64) 85/103 (82) <0.01
Anti-DNA antibodies ever 96/146 (66) 67/103 (65) 1.00
Low complement at study point 48/143 (34) 40/101 (40) 0.40
Prednisone at study point 89/146 (61) 63/103 (62) 1.00
Azathioprine at study point 18/146 (12) 18/103 (18) 0.34
Cyclophosphamide at study point 2/146 (1) 3/103 (3) 0.69
Methotrexate at study point 12/146 (8) 3/103 (3) 0.144
Mycophenolate at study point 6/146 (45) 0/103 (0) 0.04
SDI = 0 121/146 (83) 61/103 (59)  
SDI = 1 to 2 25/146 (17) 35/103 (34) 0.001
SDI >2 0/146 (0) 7/103 (7)  
SLEDAI at diagnosis 9 (1 to 22) 9 (2 to 25) 0.94
SLEDAI at study point 4 (0 to 21) 3 (0 to 24) 0.84
SLEDAI at diagnosis >12 33/143 (23) 25/101 (25) 0.88
SLEDAI at study point >12 6/143 (4) 6/101(6) 0.75
  1. Data presented as mean (standard deviation), n/N (%) or median (range). SDI, Systemic Lupus International Collaborating Clinics Damage Index; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.